Clone/AB feature:

(#7G96)

Antibody generation:

This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human VEGFR-1 N-terminal recombinant protein. IgG1 fraction of the tissue culture supernatant was purified by Protein G affinity chromatography.

Antigen:

recombinant human VEGFR1 N-terminal fragment

Stability:

Lyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20 °C for at least for six months without detectable loss of activity.

Reconstitution:

Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.

Description:

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVE supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. Relia Tech类似于我们在大肠杆菌中的蛋白质表达服务，我们还提供了围绕昆虫细胞中基因和蛋白质表达（尤其是信号蛋白质）的模块化服务系统。ReliaTech的“杆状病毒表达服务（BVS）”分为一系列步骤，这些步骤可以单独执行或组合执行，因此您可以选择实际需要的步骤。这些服务旨在充分满足从基因表达到蛋白质纯化的所有特定需求-从通过重组杆状病毒构建，高滴度重组杆状病毒生产，重组蛋白批量生产以及最终蛋白质纯化的基因克隆到杆状病毒转移载体开始。所有步骤均在无血清培养基中进行，以确保安全性并产生高纯度的重组蛋白。除常规项目更新外，您还将在每个服务步骤的最后收到进度报告。我们将根据您的授权逐步指导您继续进行。